Nowe perspektywy leczenia przeciwzakrzepowego — środki hamujące czynnik krzepnięcia XI

In the recent years coagulation factor XI (fXI) has emerged as one of the main contributors to the pathogenesis of thrombosis. Results of the experimental studies, performed on animal models, as well as, results of phase I/II studies with fXI antisense oligonucleotide in human, indicate, that selective fXI inhibition provides antithrombotic benefits without compromising the hemostasis. In paper, different modes of fXI inhibition were described. Potential limitations of this novel antithrombotic therapy were also discussed.